Skip to main content

Advertisement

Log in

A randomized study comparing epirubicin in a 4-weekly versus a weekly intravenous regimen in patients with metastatic, hormone resistant, prostatic carcinoma: effects on health related quality of life

  • Free Paper
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

The treatment of hormone resistant prostate cancer) with epirubicin 25 mg/m2 (Epi25) on a weekly intravenous regimen may be better in terms of health related quality of life (HRQOL) than with 100 mg/m2 (Epi100) on a 4-weekly regimen. A total of 79 patients who filled out the EORTC-QLQ-C30 questionnaire for the assessment of HRQOL could be evaluated. Compared with the baseline, no changes in HRQOL function scales or significant changes in the following HRQOL symptom scales were found. The Epi25 group reported less pain during the first 3 months and the Epi100 group more dyspnoea after 4 weeks and less pain and less insomnia but more loss of appetite after 8 weeks. In both groups, toxicity was comparable, except for World Health Organisation grade II-III alopecia occurring in 82% in the Epi100 versus 31% in the Epi25 group. There were no significant differences between groups in response rates and survival. In this study, HRQOL was not improved which is in line with other studies using only epirubicine. Epirubicin as single agent therapy should not be used in future treatment of patients with HRPC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al. (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365–376

    PubMed  Google Scholar 

  2. Brausi M, Jones WG, Fossa SD, de Mulder PH, Droz JP, Lentz MA et al. (1995) High dose epirubicin is effective in measurable metastatic prostate cancer: a phase II study of the EORTC Genitourinary Group. Eur J Cancer 31A:1622–1626

    Article  CAS  PubMed  Google Scholar 

  3. Burk K, Schultze-Seemann W, Jonas D, Rodeck G (1989) Weekly epirubicin in patients with hormone refractory prostatic cancer, a two-year follow-up. Prog Clin Biol Res 303:277–285

    CAS  PubMed  Google Scholar 

  4. Chapman GB, Elstein AS, Kuzel TM, Sharifi R, Nadler RB, Andrews A et al. (1998) Prostate cancer patients' utilities for health states: how it looks depends on where you stand. Med Decis Making 18:278–286

    CAS  PubMed  Google Scholar 

  5. Chapman GB, Elstein AS, Kuzel TM, Nadler RB, Sharifi R, Bennett CL (1999) A multi-attribute model of prostate cancer patient's preferences for health states. Qual Life Res 8:171–180

    Article  CAS  PubMed  Google Scholar 

  6. Collette L (2001) Compliance of quality of life assessment in EORTC GU trials. Eur Organ Res Treat Cancer-Genito Urinary Group Newslett 7:43–51

    Google Scholar 

  7. Dawson NA, McLeod DG (1997) The assessment of treatment outcomes in metastatic prostate cancer: changing endpoints. Eur J Cancer 33:560–565

    Article  CAS  PubMed  Google Scholar 

  8. Dawson NA, Conaway M, Halabi S, Winer EP, Small EJ, Lake D et al. (2000) A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181. Cancer 88:825–834

    Article  CAS  PubMed  Google Scholar 

  9. Delaere KP, Leliefeld H, Peulen F, Stapper EW, Smeets J, Wils J (1992) Phase II study of epirubicin in advanced hormone-resistant prostatic carcinoma. Br J Urol 70:641–642

    CAS  PubMed  Google Scholar 

  10. Da Silva FC, Fossa SD, Aaronson NK, Serbouti S, Denis L, Casselman J et al. (1996) The quality of life of patients with newly diagnosed M1 prostate cancer: experience with EORTC clinical trial 30853. Eur J Cancer 32A:72–77

    PubMed  Google Scholar 

  11. Fossa SD, Slee PH, Brausi M, Horenblas S, Hall RR, Hetherington JW et al. (2001) Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. J Clin Oncol 19:62–71

    CAS  PubMed  Google Scholar 

  12. Francini G, Petrioli R, Manganelli A, Cintorino M, Marsili S, Aquino A et al. (1993) Weekly chemotherapy in advanced prostatic cancer. Br J Cancer 67:1430–1436

    CAS  PubMed  Google Scholar 

  13. Jones WG, Fossa SD, Bono AV, Klijn JG, De Pauw M, Sylvester R (1987) European Organization for Research and Treatment of Cancer (EORTC) phase II study of low-dose weekly epirubicin in metastatic prostate cancer. Cancer Treat Rep 71:1317–1318

    CAS  PubMed  Google Scholar 

  14. Kish JA, Bukkapatnam R, Palazzo F (2001) The treatment challenge of hormone-refractory prostate cancer. Cancer Control 8:487–495

    CAS  PubMed  Google Scholar 

  15. Knox JJ, Moore MJ (2001) Treatment of hormone refractory prostate cancer. Semin Urol Oncol 19:202–211

    CAS  PubMed  Google Scholar 

  16. Kornblith AB, Herndon JE, Zuckerman E, Godley PA, Savarese D, Vogelzang NJ (2001) The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: a feasibility study. Ann Oncol 12:633–641

    Article  CAS  PubMed  Google Scholar 

  17. Litwin MS, Fitzpatrick JM, Fossa SD, Newling DW (1999) Defining an international research agenda for quality of life in men with prostate cancer. Prostate 41:58–67

    Article  CAS  PubMed  Google Scholar 

  18. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214

    PubMed  Google Scholar 

  19. Moore MJ, Tannock IF (1996) Overview of Canadian trials in hormonally resistant prostate cancer. Semin Oncol 23 (Suppl 14):15–19

    CAS  Google Scholar 

  20. Osoba D, Tannock IF, Ernst DS, Neville AJ (1999) Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone. J Clin Oncol 17:1654–1663

    CAS  PubMed  Google Scholar 

  21. Schmid HP, Maibach R, Bernhard J, Hering F, Hanselmann S, Gusset H et al. (1997) A phase II study of oral idarubicin as a treatment for metastatic hormone-refractory prostate carcinoma with special focus on prostate specific antigen doubling time. Swiss Group for Clinical Cancer Research, Berne, Switzerland. Cancer 79:1703–1709

    Article  CAS  PubMed  Google Scholar 

  22. Singer PA, Tasch ES, Stocking C, Rubin S, Siegler M, Weichselbaum R (1991) Sex or survival: trade-offs between quality and quantity of life. J Clin Oncol 9:328–334

    CAS  PubMed  Google Scholar 

  23. Small EJ, Meyer M, Marshall ME, Reyno LM, Meyers FJ, Natale RB et al. (2000) Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol 18:1440–1450

    CAS  PubMed  Google Scholar 

  24. Smith DC, Esper P, Strawderman M, Redman B, Pienta KJ (1999) Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol 17:1664–1671

    CAS  PubMed  Google Scholar 

  25. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ et al. (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14:1756–1764

    CAS  PubMed  Google Scholar 

  26. Van Andel G, Kurth KH, Rietbroek RL, van De Velde-Muusers JA (2000) Quality of life assessment in patients with hormone-resistant prostate cancer treated with epirubicin or with epirubicin plus medroxy progesterone acetate—is it feasible? Eur Urol 38:259–264

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to W. P. J. Witjes.

Rights and permissions

Reprints and permissions

About this article

Cite this article

van Andel, G., Fernandez de Moral, P., Caris, C.T.M. et al. A randomized study comparing epirubicin in a 4-weekly versus a weekly intravenous regimen in patients with metastatic, hormone resistant, prostatic carcinoma: effects on health related quality of life. World J Urol 21, 177–182 (2003). https://doi.org/10.1007/s00345-003-0342-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-003-0342-3

Keywords

Navigation